RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 14 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 14

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  2. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  3. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  4. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  5. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  6. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  7. Study siteLiuzhou People's Hospital柳州市人民医院LiuzhouHospital page
  8. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  9. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  10. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  11. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
  12. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  13. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  14. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05956587, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma;

    Inclusion criterion 5

  3. For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent;

    Exclusion criterion 1

  4. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    Inclusion criterion 9

    Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;

    Exclusion criterion 3

  5. ECOG 0 or 1;

    Inclusion criterion 8

  6. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements;

    Inclusion criterion 11

    Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN;

    Inclusion criterion 12

  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    Inclusion criterion 7

  8. Other malignancies diagnosed within 5 years before the first dose;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05956587, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign the informed consent form voluntarily and follow the protocol requirements;
  • Gender is not limited;
  • Age: ≥18 years old and ≤75 years old;
  • Expected survival time ≥3 months;
  • Patients with histologically and/or cytologically confirmed locally advanced or metastatic solid tumors such as non-small cell lung cancer and nasopharyngeal carcinoma;
  • Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
  • At least one measurable lesion meeting the RECIST v1.1 definition was required;
  • ECOG 0 or 1;
  • The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  • No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  • No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the level of organ function must meet the requirements;
  • Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time≤1.5 ULN;
  • Urinary protein ≤2+ or ≤1000mg/24h;
  • For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

  • For stage 3 Cohort_A, patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent;
  • Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
  • Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis;
  • Use of immunomodulatory drugs within 14 days before the first dose of study drug;
  • History of severe heart disease;
  • QT prolongation, complete left bundle branch block, III degree atrioventricular block;
  • Systemic corticosteroids or immunosuppressive agents are required within 2 weeks before study dosing;
  • Active autoimmune and inflammatory diseases;
  • Other malignancies diagnosed within 5 years before the first dose;
  • Hypertension poorly controlled by two antihypertensive drugs;
  • Pulmonary disease was defined as grade ≥3 according to CTCAE v5.0; Patients with current or history of ILD;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • Patients with a large amount of serous cavity effusion, or serous cavity effusion with symptoms, or within 4 weeks before signing informed consent;
  • Patients with active central nervous system metastases;
  • Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipients of the test drug;
  • Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  • Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;
  • Active infection requiring systemic therapy;
  • Had participated in another clinical trial within 4 weeks before the first dose;
  • The investigator did not consider it appropriate to use other conditions for participation in the trial.

Quoted from ClinicalTrials.gov, NCT05956587, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05956587, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05956587